Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin
Erlotinib, a specific epidermal growth factor receptor tyrosine kinase inhibitor, is used to treat various metastatic cancers. It is known to cause an acneiform rash. Herein, we report a case where the rash spared the previous radiotherapy field. A limitation of this study is that it is an anecdotal case report. Further research into the pathologic process of the rash is warranted to understand the reason for its absence in the irradiated skin.
aDepartment of Clinical Oncology, St James's Institute of Oncology, Leeds, United Kingdom
bDepartment of Dermatology, York District Hospital, York, United Kingdom
Correspondence to: Jayati Acharya, MRCP, Department of Clinical Oncology, St James's Institute of Oncology, Beckett Street, Leeds, West Yorkshire, United Kingdom LS9 7TF.